Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 17Withdrawn 4Terminated 3Unknown 2Recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Colorectal Neoplasms 37Recurrence 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 28Lymphoma 26Pancreatic Neoplasms 25Melanoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Leukemia 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

Certolizumab Pegol 2Ustekinumab 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Crohn Disease × Clear all
NCT04971525 2025-07-08

A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer

Takeda

Withdrawn

Crohn Disease

NCT04655807 2025-04-27

DUET

Janssen Research & Development, LLC

Phase 2 Withdrawn

Crohn Disease

NCT00354367 2012-05-28

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

UCB Pharma

Phase 3 Withdrawn

Crohn Disease, Fistula

NCT00358683 2012-05-28

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

UCB Pharma

Phase 3 Withdrawn

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡